Southern Capital Advisors LLC Trims Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Southern Capital Advisors LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 25.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,791 shares of the company’s stock after selling 618 shares during the period. Southern Capital Advisors LLC’s holdings in Johnson & Johnson were worth $290,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Gemmer Asset Management LLC grew its position in shares of Johnson & Johnson by 39.1% during the third quarter. Gemmer Asset Management LLC now owns 8,375 shares of the company’s stock worth $1,357,000 after buying an additional 2,356 shares in the last quarter. FCG Investment Co grew its position in shares of Johnson & Johnson by 219.1% during the third quarter. FCG Investment Co now owns 14,409 shares of the company’s stock worth $2,335,000 after buying an additional 9,894 shares in the last quarter. Insight Folios Inc grew its position in shares of Johnson & Johnson by 6.2% during the third quarter. Insight Folios Inc now owns 43,421 shares of the company’s stock worth $7,037,000 after buying an additional 2,522 shares in the last quarter. IVC Wealth Advisors LLC grew its position in shares of Johnson & Johnson by 2.2% during the third quarter. IVC Wealth Advisors LLC now owns 10,944 shares of the company’s stock worth $1,774,000 after buying an additional 232 shares in the last quarter. Finally, First Financial Bankshares Inc grew its position in shares of Johnson & Johnson by 10.7% during the third quarter. First Financial Bankshares Inc now owns 630,066 shares of the company’s stock worth $102,108,000 after buying an additional 61,076 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the subject of a number of analyst reports. TD Cowen lowered their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. The Goldman Sachs Group lowered their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Citigroup upped their price target on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a report on Wednesday, October 16th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Finally, StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, September 14th. Six equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $175.93.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $160.14 on Wednesday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $168.85. The stock has a 50 day moving average of $163.45 and a two-hundred day moving average of $155.28. The stock has a market cap of $385.41 billion, a P/E ratio of 9.98, a P/E/G ratio of 2.90 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, topping the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.46% and a net margin of 19.14%. The business had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. During the same quarter in the prior year, the business earned $2.66 earnings per share. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. On average, research analysts forecast that Johnson & Johnson will post 9.94 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.10%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 30.92%.

Insider Transactions at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.